EUnetHTA Plenary Assembly

April 10-11, 2014 Madrid, Spain





European network for Health Technology Assessment | JA2 2012-2015 | www.eunethta.eu

Mid-term EUnetHTA strategic development (JA3 – (2016-2020)

Juergen Hohmann, rapporteur of the green WG



European network for Health Technology Assessment | JA2 2012-2015 | www.eunethta.eu

1. Achievements in JA3?

Prioritize outputs

Better linking international production and national uptake

2020

EUnetHTA

2016

- Enhancing the national implementation of guidelines
- Making countries/national partners more accountable
 - Setting benchmarking and apply peer-review processes
- Closing the gap between countries/agencies of different levels of HTA performance
 - Formation of country clusters based on level of commitments and activity priorities
- Better advocating HTA
 - Intensify marketing from scientific level
 - Develop a communication plan for HTA production

Leverage synergies

- between national and international level
- Retween strategic and scientific/technical level

eunethta

European network for Health Technology Assessment | JA2 2012-2015 | w

2. What will define priorities of specific activities for JA3?

- An extensive stock-taking exercise should allow identifying activities with highest potential for collaboration
 - only these should be continued
- The commitment to apply HTA to a whole range of health technologies should be reflected by
 - Addressing 1-2 large non-pharmaceutical issues by joint pilot production
 - The selection can be done on strategic level
 - High potentials: ICT-enabled programs, prevention, surgical procedures
 - The scientific level will perform the assessment
 - Context specific dimensions should be given utmost attention



3. Overcome limitations

- Better Identify limitations with the help of an independent HTA auditor
 - To assess national usage, legal restrictions and diversity of HTA products
 - A report of the results should be made available by 2016
 - Only EUnetHTA products with highest potential of collaboration should be continued
- Professionalize the process of HTA production
 - Supplement the voluntariness with objective criteria of required technical capacities
 - Each topic should undergo a separate tender process
 - The EMA Committee for Medicinal Products for Human Use (CHMP) serves as example of good practice
- Implement more flexible measures of collaboration
 - Ad hoc «enhanced collaboration» by a number of members
 - It requires a budget line to support such work
 - JA3 may also provide possibilities of sub-contracting




4. Modes of operation

- The different levels of collaboration should be continued
 - 1: Sharing and exchange of information
 - 2: Development of common generic guidelines
 - 3: Application of standards and tool at national/regional level
 - The commitments, however, should me made more specific
 - And countries need to be made accountable to perform accordingly



5. Relation between HTAN and scientific and technical cooperation

- **Building and leveraging synergies** -
 - EUnetHTA acts as scientific partner to HTAN _
 - Strengthen relationships between national agencies and representatives in HTAN



6. Which processes of JA2 should be further improved

- Topic selection
 - WP5 Dependency of manufacture interest interferes with the topic selection according to needs
 - Obsolete technologies could be taken into account

Stakeholder involvement

- Appropriateness of the stakeholder forum to be reconsidered
- Better involvement of stakeholders in all WPs

- Guidelines development

- Implement processes for revision and development

Training activities

- Find a good balance between f-t-f and e-learning training activities

